Valeant is leaping after reporting mixed earnings (vrx)

Shares of troubled drugmaker Valeant Pharmaceuticals are taking off after the company reported mixed earnings on Tuesday morning.
Valeant earned an adjusted $1.40 per share ($1.47 expected) on revenue of $2.42 billion ($2.46 billion expected) during the second quarter. The firm did, however, beat on GAAP earnings with a loss of $0.88 (-$0.92 expected).
"We continue to make progress towards stabilizing the organization," CEO Joseph Papa said in a press release accompanying the earnings.
"We are a